press-releases

Lunaphore announces new approach on interrogating the tumor microenvironment using COMET™ and deep learning tools at the 28th Congress of the European Association for Cancer Research

Lunaphore announces new approach on interrogating the tumor microenvironment using COMET™ and deep learning tools at the 28th Congress of the European Association for Cancer Research

Company will also host sponsored symposium on high-plex spatial proteomics on June 20

LAUSANNE, Switzerland – June 14, 2022 – 11:00 am (CEST)Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, today announced new research using its flagship COMET™ spatial biology platform and Indica Labs’ HALO® and HALO AI™ image analysis software to characterize the tumor microenvironment across different tumor types. The research will be presented at the 28th Congress of the European Association for Cancer Research (EACR) in Seville, Spain, on June 21, 2022 from 5:00 pm – 6:00 pm CEST in Poster Section 1 (poster board number: P1-541).

The poster, titled “Depicting the cellular architecture of the tumor microenvironment by integrating hyperplex immunofluorescence and automated image analysis,” will showcase how the COMET™ platform was used to characterize cells in the tumor microenvironment across different tumor types using an immuno-oncology panel encompassing 20 biomarkers. After obtaining images using COMET™, researchers developed a deep learning classifier using Indica’s HALO® and HALO AI™ image analysis software to automatically identify the tumor and stroma areas. This classifier was then used to further quantify subpopulations of tumor and immune cells of the tumor microenvironment such as lymphocytes and macrophages within the different areas of the tissue. The immune cell–tumor interaction was interrogated by analyzing cell proximity to the tumor and exploration of the infiltration patterns.

Figure 1. Detection and classification of immune cell subtypes. (A) Raw multiplex immunofluorescence image, (B) close up multiplex immunofluorescence image (nuclei in blue, tumour cells in cyan, CD45 in orange, CD3 in red, CD4 in pink, CD8 in yellow, Ki67 in white, PD-L1 in green, FOXP3 in purple), (C) cell classification/analysis mark-up (colocalization).

“Our study demonstrated that COMET™ can provide a robust workflow to interrogate the composition of the tumor microenvironment that is easily adaptable to any tissue and any set of markers,” said Diego G. Dupouy, Ph.D., Chief Technology Officer at Lunaphore. “Furthermore, the synergy between COMET™ and Indica’s HALO® and HALO AI™ image analysis software provides a seamless path to ease adoption of multiplex immunofluorescence technology and data analysis for scientists at every stage of their research.”

 

Sponsored Symposium on High-plex Spatial Proteomics

Lunaphore will also host a sponsored symposium titled “High-plex spatial proteomics made easy with automated sequential IF: how to get most of your research” on June 20, 2022 at 12:45 p.m. CEST in Auditorium 2 and 3. Charlotte Stadler, Ph.D., Head of the National Spatial Proteomics Facility at SciLifeLab, will discuss use cases of COMET™ from the perspective of a core facility. Dr. Dupouy will provide an overview of COMET™ for hyperplex sequential immunofluorescence (seqIF™) and how to maximize the technology.

 

 

To learn more about Lunaphore’s presentations at EACR, please visit: https://lunaphore.com/news/our-events/eacr-2022-annual-meeting/

To learn more about Lunaphore, please visit: https://lunaphore.com/

 

 

About COMET™

COMET™ is a fully automated sequential immunofluorescence (seqIF™) instrument, able to perform hyperplex staining and imaging, producing high-quality data in a robust and reproducible manner. With superior tissue profiling capabilities, the system allows multiplex analysis of up to 40 different spatial markers per tissue slide without human intervention. COMET™ has a wide range of research applications, allowing for a dramatic improvement in the understanding of disease pathology in areas such as immuno-oncology, neuroscience, and infectious diseases. The technology has the ability to revolutionize clinical applications such as drug discovery and biomarker development.

COMET™ is currently available through a Priority Access Program. To learn more about the COMET™ platform, please visit: https://lunaphore.com/products/comet/

 

About Lunaphore

Lunaphore Technologies S.A. is a Swiss company born in 2014 with the vision of enabling spatial biology in every laboratory. Lunaphore has developed a game-changing chip technology which can extract spatial proteomic and genomic data from tumors and transform any simple assay into multiplex spatial biology without complexity. Lunaphore empowers researchers to push the boundaries of research to ultimately develop the next generation personalized therapies. For further information on Lunaphore and its products, please visit www.lunaphore.com.

 

 

 

For further information contact:

Irene Tamayo

Lunaphore Corporate Communications

Email: [email protected]